Beneath Tuesday's flashy news that the Biden administration wants Medicare to cover a blockbuster obesity drug lies a less flashy but potentially influential force to improve private Medicare plans. A certain idea was hidden a little.
Centers for Medicare and Medicaid Services proposed rule It signals technical and policy changes for Medicare Advantage and Medicare Part D plans that cover prescription drugs by 2026. The incoming Trump administration will have final say on which proposals are finalized and which are repealed.
More than half of people enrolled in Medicare, the program for seniors and people with disabilities, are currently enrolled in Medicare Advantage plans, but government watchdogs and others say they are denied the care they need and that millions of people each year are denied the care they need. Always aware that it collects billions of dollars in questionable payments. The plan announced Tuesday aims to tackle everything from the use of artificial intelligence to misleading marketing, coverage barriers and inaccurate provider directories.
This article is exclusive to STAT+ subscribers
Subscribe to STAT+ for this article and daily analysis of market-moving biopharmaceuticals.
Already have an account? Log in
See all plans
